Browsing Tag
ROCKET Program
1 post
Amgen and Kyowa Kirin report Phase 3 rocatinlimab results highlighting long-term safety and durable response in atopic dermatitis
Amgen and Kyowa Kirin report Phase 3 rocatinlimab results showing long-term safety and durable efficacy in atopic dermatitis. Find out what comes next.